Literature DB >> 15251435

Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells.

Calley L Hirsch1, Keith Bonham.   

Abstract

Histone deacetylase inhibitors (HDIs) are thought to act primarily at the level of transcription inducing cell cycle arrest, differentiation and/or apoptosis in many cancer cell types. Induction of the potent cdk/cyclin inhibitor p21WAF1 is a key feature of this HDI mediated transcriptional re-programming phenomenon. However, in the current study we report that HDIs are also capable of inducing p21WAF1 through purely post-transcriptional events, namely increased mRNA stability. These studies highlight our growing appreciation for the complexities of HDI mediated effects and challenge our preconceptions regarding the action of these promising anti-neoplastics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251435     DOI: 10.1016/j.febslet.2004.06.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

Review 1.  The promise and failures of epigenetic therapies for cancer treatment.

Authors:  Pasano Bojang; Kenneth S Ramos
Journal:  Cancer Treat Rev       Date:  2013-07-05       Impact factor: 12.111

2.  Ferritin H induction by histone deacetylase inhibitors.

Authors:  Wei Wang; Xiumin Di; Suzy V Torti; Frank M Torti
Journal:  Biochem Pharmacol       Date:  2010-04-10       Impact factor: 5.858

3.  Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

Authors:  Yu-Wei Chou; Nagendra K Chaturvedi; Shougiang Ouyang; Fen-Fen Lin; Dharam Kaushik; Jue Wang; Isaac Kim; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2011-07-22       Impact factor: 8.679

4.  Integrated Metabolomics, Transcriptomics and Proteomics Identifies Metabolic Pathways Affected by Anaplasma phagocytophilum Infection in Tick Cells.

Authors:  Margarita Villar; Nieves Ayllón; Pilar Alberdi; Andrés Moreno; María Moreno; Raquel Tobes; Lourdes Mateos-Hernández; Sabine Weisheit; Lesley Bell-Sakyi; José de la Fuente
Journal:  Mol Cell Proteomics       Date:  2015-09-30       Impact factor: 5.911

Review 5.  Nonhistone protein acetylation as cancer therapy targets.

Authors:  Brahma N Singh; Guanghua Zhang; Yi L Hwa; Jinping Li; Sean C Dowdy; Shi-Wen Jiang
Journal:  Expert Rev Anticancer Ther       Date:  2010-06       Impact factor: 4.512

Review 6.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

7.  Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.

Authors:  Imke Müller; Frank Wischnewski; Klaus Pantel; Heidi Schwarzenbach
Journal:  BMC Cancer       Date:  2010-06-17       Impact factor: 4.430

Review 8.  Chromatin-modifying enzymes as therapeutic targets--Part 1.

Authors:  Brian R Keppler; Trevor K Archer
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

9.  Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation.

Authors:  Yu-Gang Wang; Ling Xu; Ting Wang; Jue Wei; Wen-Ying Meng; Na Wang; Min Shi
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

10.  Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes.

Authors:  Alvaro Rada-Iglesias; Stefan Enroth; Adam Ameur; Christoph M Koch; Gayle K Clelland; Patricia Respuela-Alonso; Sarah Wilcox; Oliver M Dovey; Peter D Ellis; Cordelia F Langford; Ian Dunham; Jan Komorowski; Claes Wadelius
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.